Prostate cancer screening

[摘要] To the Editor: To make screening recommendations, including for PSA, one must consider an unbiased assessment of benefits, risks, and costs. Yet Sooriakumaran1 fails to discuss current guidelines or the harms of screening, and falsely claims a mortality benefit. Gilligan’s accompanying editorial2 fails to quantify those harms and briefly mentions the guidelines without giving the rationale to avoid screening. Both emphasize European Randomised Study of Screening for Prostate Cancer results showing a 20% relative risk reduction in disease-specific mortality.

[学科分类] 卫生学